Scope Fluidics Group, operating in the life science sector and listed on the Warsaw Stock Exchange, develops innovative technologies for the medical diagnostics and healthcare markets. As of the end of the third quarter of 2025, the Group held more than PLN 110 million in cash, including approximately PLN 23 million in investment fund units. In addition, in October this year, the Group raised more than PLN 64 million in cash through a share issuance.
Shortly after the end of the third quarter, the Group signed an agreement with Perella Weinberg Partners, a highly regarded U.S.-based transaction advisor, marking another step in the process of securing a global business partner for the BACTEROMIC system. The Group also appointed an international Clinical Advisory Board to support further development of BACTEROMIC.
The Group continues to develop two new companies originating from Scope Discovery – EDOCERA, which has completed its technology verification phase and begun work on a device prototype, and HYBOLIC.
We continue to execute our projects and strengthen Scope Fluidics’ position in breakthrough diagnostic technologies. BACTEROMIC remains the priority, with progress confirmed by internal PoC tests for the UNI FAST and PBC panels. In parallel, we are intensifying regulatory activities: we have submitted the full IVDR certification dossier for the BACTEROMIC system equipped with the UNI Panel, and expanded cooperation with our FDA certification advisor. This will enable us to seek authorization for the extended UNI FAST Panel with more drug-bug combinations than originally anticipated. Global industry partners and advisors recognize the potential of the BACTEROMIC system, and the agreement with a top-tier transaction advisor is a natural step toward advancing our flagship project. Our partner’s AST expertise reinforces our conviction that we will fully unlock the potential of BACTEROMIC, while also providing meaningful support for our international activities. It also confirms the consistent pursuit of Scope Fluidics Group’s long-term strategy. At the same time, we continue to advance our other projects – EDOCERA and HYBOLIC. Following successful technology verification, EDOCERA has started R&D work on a prototype stroke-prevention and diagnostic device, a solution with potentially groundbreaking public-health implications. By developing projects with global potential and strengthening our market position we intend to continue growing and increasing our international standing – says Piotr Garstecki, CEO of Scope Fluidics.
Scope Fluidics has appointed Perella Weinberg Partners (PWP) as its transaction advisor. PWP is a global independent investment advisory firm employing more than 700 professionals in 10 offices worldwide. Since its inception, the firm has advised on transactions exceeding USD 1 trillion in total value, including more than USD 200 billion in healthcare transactions since 2011. The healthcare team includes more than 65 specialists, among them 9 partners. PWP has extensive knowledge and experience in the AST sector through its work with numerous clients in this field and has served as financial advisor on many successful transactions.
In addition, Bacteromic has established an international Clinical Advisory Board. This team of independent clinical experts will support the development of the Group’s most expanded project, the BACTEROMIC system. The board includes specialists from the United Kingdom, Italy, and the United States, and will advise Bacteromic on aligning the system with detailed clinical and market needs. This input will be crucial for further advancing the Group’s diagnostic technologies and supporting their commercialization in international markets.
Strengthening the cash position
At the end of the third quarter of 2025, the Group held more than PLN 110 million in cash – approximately PLN 87 million in cash and bank deposits, and around PLN 23 million in investment fund units.
In October 2025, Scope Fluidics carried out a private placement of Series K shares. The shares were acquired at an issue price of PLN 145 each, and the total value of the placement exceeded PLN 64 million.
Today, most of our investment efforts focus on the BACTEROMIC project, as we prepare the company for a planned M&A transaction. Developing technology with such a high degree of innovation is a multi-year undertaking that requires not only unique know-how but also financial stability and a deliberate approach to planning expenditures. For this reason, we consistently safeguard a strong cash position and diversify capital sources – this provides us with greater operational flexibility and strengthens our negotiating position in key processes. A significant element of this approach was the recent private placement of Series K shares, which materially reinforced our financial resources – emphasizes Szymon Ruta, Vice President and Chief Financial Officer of Scope Fluidics.
Work on new projects
Scope Fluidics is also continuously advancing new initiatives. Scope Discovery – the Group’s internal venture studio – is responsible for identifying and developing new concepts, operating on the basis of a structured and repeatable project-creation process.
At the end of the third quarter, Scope Discovery’s pipeline included 63 initiatives: 28 had already been completed, 11 were under analysis and development, and 22 were awaiting evaluation. Two initiatives – EDOCERA (DSC001) and HYBOLIC (DSC027) – have been selected for development within dedicated special-purpose entities.
